Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?

Overview

Journal Case Rep Oncol

Publisher Karger

Specialty Oncology

Date 2018 Feb 13

PMID 29430237

Citations 1

Authors

Andreas Blesl

Elisabeth Krones

Marion J Pollheimer

Johannes Haybaeck

Ulrike Wiesspeiner

Rainer W Lipp

Patrizia Kump

Affiliations

Soon will be listed here.

Abstract

The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs, mTOR inhibitors, or cytotoxic substances. This case illustrates downgrading of a primarily highly proliferative NET achieved by a variation of cytotoxic chemotherapy regimens, followed by a combination therapy using everolimus together with lanreotide. The latter medication might lead to a good clinical response as far as tumor growth is concerned.

Citing Articles

Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms.

Reccia I, Pai M, Kumar J, Spalding D, Frilling A Cancers (Basel). 2023; 15(6).

PMID: 36980746 PMC: 10047148. DOI: 10.3390/cancers15061861.

References

Velayoudom-Cephise F, Duvillard P, Foucan L, Hadoux J, Chougnet C, Leboulleux S . Are G3 ENETS neuroendocrine neoplasms heterogeneous?. Endocr Relat Cancer. 2013; 20(5):649-57. DOI: 10.1530/ERC-13-0027. View

Tang L, Gonen M, Hedvat C, Modlin I, Klimstra D . Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012; 36(12):1761-70. DOI: 10.1097/PAS.0b013e318263207c. View

Correale P, Sciandivasci A, Intrivici C, Pascucci A, Del Vecchio M, Marsili S . Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation. Br J Cancer. 2007; 96(9):1343-7. PMC: 2360193. DOI: 10.1038/sj.bjc.6603734. View

Kos-Kudla B . Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study. Contemp Oncol (Pozn). 2016; 19(5):345-9. PMC: 4709401. DOI: 10.5114/wo.2015.56006. View

Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D . Everolimus in Pancreatic Neuroendocrine Carcinomas G3. Pancreas. 2017; 46(3):302-305. DOI: 10.1097/MPA.0000000000000762. View

Basturk O, Tang L, Hruban R, Adsay V, Yang Z, Krasinskas A . Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014; 38(4):437-47. PMC: 3977000. DOI: 10.1097/PAS.0000000000000169. View

Oberg K, Knigge U, Kwekkeboom D, Perren A . Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii124-30. DOI: 10.1093/annonc/mds295. View

Tang L, Basturk O, Sue J, Klimstra D . A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016; 40(9):1192-202. PMC: 4988129. DOI: 10.1097/PAS.0000000000000662. View

Ilett E, Langer S, Olsen I, Federspiel B, Kjaer A, Knigge U . Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel). 2016; 5(2):119-76. PMC: 4665594. DOI: 10.3390/diagnostics5020119. View

10.

Pavel M, Hainsworth J, Baudin E, Peeters M, Horsch D, Winkler R . Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011; 378(9808):2005-2012. DOI: 10.1016/S0140-6736(11)61742-X. View

11.

Sorbye H, Welin S, Langer S, Vestermark L, Holt N, Osterlund P . Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2012; 24(1):152-60. DOI: 10.1093/annonc/mds276. View

12.

Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K . Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 2014; 105(9):1176-81. PMC: 4462387. DOI: 10.1111/cas.12473. View

13.

Delektorskaya V, Kozlov N, Chemeris G . Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system. Klin Lab Diagn. 2014; (10):48-50, 10-3. View

14.

Gilabert M, Rho Y, Kavan P . Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas. Oncology. 2016; 92(3):170-172. DOI: 10.1159/000452279. View

15.

Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P . Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocr Relat Cancer. 2010; 18(1):51-9. DOI: 10.1677/ERC-09-0319. View

16.

Yoo C, Cho H, Song M, Hong S, Kim K, Chang H . Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer Chemother Pharmacol. 2016; 79(1):139-146. DOI: 10.1007/s00280-016-3215-3. View

17.

Fazio N, Milione M . Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Cancer Treat Rev. 2016; 50:61-67. DOI: 10.1016/j.ctrv.2016.08.006. View